Vertex Pharmaceuticals (VRTX)

New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term.

President Donald Trump threatened 100% tariffs on some drug imports.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Uncertainty is in the air. But these stocks inspire confidence.

Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Look beyond the recent headwinds these two have faced.

Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector.

The stock has soared in the triple-digits over the past decade.

Here's why you can't find a Wall Street analyst who will tell you to sell this stock.

They trade at some incredibly low earnings multiples.

Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors.

These companies are reaching key milestones.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.